AnaptysBio, Inc.
ANAB
Rank in Stocks
#7176
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering... AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The companyโs products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Share Price
$47.97
Last synced: 2026-11-09
Market Cap
$1.43B
Change (1 day)
3.27%
Change (1 year)
114.44%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade AnaptysBio, Inc. (ANAB)
Category
Healthcare
EPS for AnaptysBio, Inc. (ANAB)
EPS as of June 2026 TTM: $4.99
According to AnaptysBio, Inc.'s latest financial reports, its current EPS (TTM) is $4.99. At the end of 2025 the company had an EPS of $-0.46, an increase over its 2024 EPS of $-5.12.
EPS history for AnaptysBio, Inc. from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $4.99 | -1,184.78% |
| 2025 | $-0.46 | -91.02% |
| 2024 | $-5.12 | -15.79% |
| 2023 | $-6.08 | 33.04% |
| 2022 | $-4.57 | 116.59% |
| 2021 | $-2.11 | 189.04% |
| 2020 | $-0.73 | -79.72% |
| 2019 | $-3.60 | 44.00% |
| 2018 | $-2.50 | 64.47% |
| 2017 | $-1.52 | 560.87% |
| 2016 | $-0.23 | -39.47% |
| 2015 | $-0.38 | -258.33% |
| 2014 | $0.24 | -110.53% |
| 2013 | $-2.28 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 213.83% |
US
|
|
| $-7.07 | -241.68% |
US
|
|
| $-5.29 | -206.01% |
AU
|
|
| $12.88 | 158.12% |
BE
|
|
| $21.56 | 332.06% |
NL
|
Questions about AnaptysBio, Inc.'s earnings per share (EPS)
What is AnaptysBio, Inc.'s earnings per share (EPS)?
AnaptysBio, Inc.'s earnings per share (EPS) over the last twelve months is $4.99, as of Jun 2026.
What was AnaptysBio, Inc.'s earnings per share (EPS) in 2025?
In 2025, AnaptysBio, Inc.'s earnings per share (EPS) was $-0.46, compared with $-5.12 in 2024.
How has AnaptysBio, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, AnaptysBio, Inc.'s earnings per share (EPS) was highest in 2025 ($-0.46) and lowest in 2023 ($-6.08).
How does AnaptysBio, Inc.'s earnings per share (EPS) compare with similar companies?
AnaptysBio, Inc.'s earnings per share (EPS) ($4.99) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.